Reporting of harms by randomised controlled trials in ophthalmology

British Journal of Ophthalmology

Volumn 98, Issue 8, 2014, Pages 1003-1008

  O'Day, Roderick ^a   Walton, Richard ^a   Blennerhassett, Richard ^b   Gillies, MarkC ^a   Barthelmes, Daniel ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; VASCULOTROPIN INHIBITOR;

ADVERSE DRUG REACTION; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOLLOW UP; HARM REPORTING; HUMAN; MEDICAL DOCUMENTATION; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIAL; MACULA; RETINA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84905099408     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304687     Document Type: Review

References (26)

1. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
2. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43. (Pubitemid 32097262)
3. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20. (Pubitemid 34441937)
4. Venning GR. Identification of adverse reactions to new drugs. II (continued): how were 18 important adverse reactions discovered and with what delays? Br Med J (Clin Res Ed) 1983;286:365-8. (Pubitemid 13149400)
5. Venning GR. Identification of adverse reactions to new drugs. II - How were 18 important adverse reactions discovered and with what delays? Br Med J (Clin Res Ed) 1983;286:289-92. (Pubitemid 13149378)
6. Venning GR. Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? Br Med J (Clin Res Ed) 1983;286:199-202. (Pubitemid 13147607)
7. Fraunfelder FW, Fraunfelder FT. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions. Am J Ophthalmol 2007;143:145-9.
8. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. (Pubitemid 39524916)
9. Ethgen M, Boutron I, Baron G, et al. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med 2005;143:20-5. (Pubitemid 40923331)
10. Haidich AB, Birtsou C, Dardavessis T, et al. The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol 2011;64:124-35.
11. Shukralla AA, Tudur-Smith C, Powell GA, et al. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res 2011;97:20-9.
12. Pitrou I, Boutron I, Ahmad N, et al. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-61.
13. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503.
14. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-70. (Pubitemid 24183163)
15. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36.
16. Giuliari GP. Diabetic retinopathy: current and new treatment options. Current Diabetes Rev 2012;8:32-41.
17. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012;379:1728-38.
18. Presta LG, Chen H, O 'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-99. (Pubitemid 27441066)
19. Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf 2007;30:93-105. (Pubitemid 46193061)
20. Cohen J. Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213-20.
21. Venables WN, Ripley BD. Modern Applied Statistics with S. New York, USA: Springer-Verlag, 2002.
22. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol 2001;1:3.
23. Gotzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;320:1058-61.
24. The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol 2001;131:167-75.
25. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events, version 4.0. May 28, 2009. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm (accessed 19 Aug 2013).
26. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.